A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib As Frontline Therapy for Patients with MYC-Aberrant Lymphoid Malignancies: The Daciphor Regimen

ASH 2020: Initial results of a trial investigating Ixazomib combined with chemoimmunotherapy for first line treatment of aggressive B-cell lymphomas.